Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda

Priotto, Gerardo, Fogg, Carole, Balasegaram, Manica, Erphas, Olema, Louga, Albino, Checchi, Francesco, Ghabri, Salah and Piola, Patrice (2006) Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clinical Trials, 1 (8), [e39]. (doi:10.1371/journal.pctr.0010039).

Abstract

Objectives -  Our objective was to compare the efficacy and safety of three drug combinations for the treatment of late-stage human African trypanosomiasis caused by Trypanosoma brucei gambiense. Design - This trial was a randomized, open-label, active control, parallel clinical trial comparing three arms. Setting - The study took place at the Sleeping Sickness Treatment Center run by Médecins Sans Frontières at Omugo, Arua District, Uganda. Participants - Stage 2 patients diagnosed in Northern Uganda were screened for inclusion and a total of 54 selected. Interventions - Three drug combinations were given to randomly assigned patients: melarsoprol-nifurtimox (M+N), melarsoprol-eflornithine (M+E), and nifurtimox-eflornithine (N+E). Dosages were uniform: intravenous (IV) melarsoprol 1.8 mg/kg/d, daily for 10 d; IV eflornithine 400 mg/kg/d, every 6 h for 7 d; oral nifurtimox 15 (adults) or 20 (children

This record has no associated files available for download.

Contributors

Author: Carole Fogg

Download statistics